Abstract

Artemisia selengensis Turcz is a perennial herb belonging to the genus Artemisia in the family Asteraceae. Known for its nutrient richness, distinct flavor, and medicinal properties, Artemisia selengensis Turcz. has garnered attention. However, its efficacy, particularly in alleviating hepatic injury, remains underexplored. This study aims to assess the therapeutic potential of the 50% ethanol extract of Artemisia selengensis Turcz. (ASTE) in a mouse model of Dibutyl phthalate (DBP)‐induced liver injury. Through multi‐omics analysis, including transcriptomics, metabolomics, and intestinal flora examination, we explored the pathways and key targets of ASTE in treating liver injury. Network pharmacology further identified the crucial components of ASTE for liver injury treatment. Our findings indicate that ASTE affects intestinal flora such as Adlercreutzia through flavonoids, particularly naringin and epicatechin. Additionally, key genes in the PPAR pathway, such as Fabp3, Fabp5, Ehhadh, and Pltp, influence glycerophospholipid metabolism, contributing to liver injury amelioration. This study sheds light on the molecular mechanisms underlying ASTE's hepatoprotective effects, laying the groundwork for its potential application as a functional food.